Skip to content

Júnia L. de Deus

Johns Hopkins Medicine

2 papers in the library · 362 citations · publishing 2023-2025

Papers

Psychedelics reopen the social reward learning critical period

Nature June 14, 2023 Romain Nardou, Young Jun Song, Noelle Wright et al. 335 citations

Psychedelic drugs share the ability to reopen a critical period for social reward learning in adult mice, and the duration of this reopening matches the length of subjective effects in humans. The reinstatement of social reward learning is accompanied by a metaplastic restoration of oxytocin-mediated long-term depression in the nucleus accumbens. Analysis of gene expression in the open versus closed state indicates that reorganization of the extracellular matrix is a common downstream mechanism. These findings suggest a unifying mechanism for psychedelics' therapeutic properties and may guide clinical use and drug design for neuropsychiatric diseases.

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 31, 2025 Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano et al. 27 citations

Psychedelics like psilocybin, LSD, and DMT show promise for reducing neuroinflammation linked to Alzheimer's, Parkinson's, and major depressive disorder. They act mainly through serotonin 5-HT2A receptors, lowering pro-inflammatory cytokines, regulating microglial activity, and shifting metabolite balance toward neuroprotection. They also influence NF-κB, PI3K/Akt, and mTOR pathways, promoting neuroplasticity and anti-inflammatory effects. Other neurotransmitter systems—glutamatergic, dopaminergic, noradrenergic, GABAergic, and cholinergic—contribute to these effects. The review highlights psychedelics as potential treatments for neuroinflammatory and neuropsychiatric disorders.